- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05502913
Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer
Fecal Microbiota Transplantation to Improve Efficacy of Immune Checkpoint Inhibitors in Metastatic Lung Cancer
Immunotherapy has recently become a main-stream treatment option in cancer care, with improved clinical outcomes in many malignancies, especially that of lung cancer. The long-term benefits of this treatment however are limited. There is therefore a critical need to distinguish predictive biomarkers of response from those of resistance, and to develop synergistic strategies for improved therapeutic response. Strong emerging evidence indicates that the gut microbiome has the ability to influence response to immunotherapy. Unlike tumor genomics, the gut microbiome is modifiable, and thus its modulation to enhance response to immunotherapy is an attractive therapeutic strategy.
Working hypothesis: Fecal Microbiota Transplant (FMT) treatment in conjunction with standard (chemo-)immunotherapy as a first-line treatment for metastatic lung cancer enhances disease control rate.
The main objective of this study is to evaluate the safety and efficacy of Fecal Microbiota Transplant (FMT) in altering response to immunotherapy in patients with metastatic lung cancer. The overall goal is to determine microbiome compositional and gene-content changes in patients who respond more efficiently to immunotherapy subsequent to FMT. This understanding may lead to future microbiome-based treatments in combination with immunotherapy to significantly increase lung cancer treatment efficacy. In this prospective clinical and molecular study, we will perform an in-depth analysis of the potential role of FMT in the context of immunotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Only a small subset of tumor types benefit from immune checkpoint inhibitor therapy, where most responders eventually develop resistance. Oral administration of Fecal Microbiota Transplantation (FMT) from treatment-responsive patients has been found to considerably improve Programmed death-ligand 1 (PD-L1)-based immunotherapy outcomes as well as inhibit tumor growth through augmented dendritic cell and T cell responses.
This study aims to investigate the safety and efficacy of FMT treatment combined with first-line (chemo-)immunotherapy in metastatic lung cancer. The study will include a thorough microbiome composition analysis of FMT donors and recipients to be correlated to clinical outcomes. In addition, blood samples will be analyzed using a novel commensal antigen microarray for rapid serum profiling.
Patients with metastatic malignancy who completely respond to immunotherapy will serve as the fecal implant donors. Dr. Arik Segal's Lab will produce capsules with one donor/capsule. In an open-label approach, patients will receive FMT on the first day of (chemo-)immunotherapy cycle one and every 3-4 weeks based on the specific (chemo-)immunotherapy protocol. Before FMT treatment, participants will receive active antibiotics. The second arm will receive standard-of-care treatment only. Study participants will be evaluated throughout the study using imaging, laboratory, vital signs, and disease status assessments until the end of the study.
Stool samples from study participants will be collected before the start of treatment during the (chemo-)immunotherapy cycle and at the end of treatment for sequencing and bioinformatics analysis of the microbiome. Blood samples will be collected from all donors at the study start and from all recipients at recruitment, on the day of each FMT administration, and at the end of treatment.
Statistics:
A one-sided test for differences in proportions and type I error of 0.05 will have a power of 88% to detect a 30% difference in response between the FMT and placebo group, for a total of 80 randomized patients, 40 in each treatment group stratified by PD-L1 status.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ismaell Massalha, M.D.
- Phone Number: +972526995934
- Email: ismaell@post.bgu.ac.il
Study Contact Backup
- Name: Amichay Meirovitz, Prof.
- Phone Number: +972528805922
- Email: amichaym@gmail.com
Study Locations
-
-
-
Beer sheva, Israel
- Recruiting
- Soroka Medical Center
-
Principal Investigator:
- Ismaell Massalha, M.D.
-
Petah Tikva, Israel
- Not yet recruiting
- Rabin Medical Center
-
Contact:
- Mor Moskovitz, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Patient (Recipient) Inclusion Criteria:
- A histologically confirmed diagnosis of malignancy.
- Patients over the age of 18.
- Patients planning to be treated with chemotherapy, immune checkpoint inhibitors and/or targeted therapy.
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- Able to provide written informed consent.
Patient (Recipient) Exclusion Criteria:
- Severe or life-threatening food allergy (e.g. nuts, seafood)
- Allergy or other contraindication to omeprazole, investigational medicinal product.
- Treatment with pre- or probiotics in the four weeks prior to randomization.
Severe immunodeficiency:
- Systemic chemotherapy <30 days from baseline
- Known neutropenia with absolute neutrophils <1.0x109 cells/µL
- Prolonged treatment with corticosteroids (equivalent to prednisone >60mg daily for >30 days) within 8 weeks of randomization
- Swallowing disorder, oral-motor discoordination, inability to swallow capsules
- Pregnant or breastfeeding or expecting to conceive or father children within the trial's projected duration, starting from the pre-screening or screening visit through to 120 days after the last dose of trial treatment.
Donor Inclusion Criteria:
- A histologically confirmed diagnosis of malignancy.
- Over the age of 18.
- Treated with immune checkpoint inhibitors and with a full response.
- Currently attending medical follow-ups
Donor Exclusion Criteria:
- Has not consumed any antimicrobials within the past 3 months
- No prior exposure to HIV or viral hepatitis or suffering from tuberculosis/latent tuberculosis
- No risk factors for blood-borne viruses, including high-risk sexual behavior, use of illicit drugs, any tattoo/body piercing/needlestick injury/blood transfusion/acupuncture, all within the past 6 months
- No signs or symptoms consistent with Coronavirus disease 19 (COVID-19) or a nose/throat and/or stool sample with detectable Coronavirus disease 2 (CoV-2)
- Has not received a live attenuated vaccine within the past 6 months
- No underlying gastrointestinal conditions/symptoms (e.g., history of IBD, irritable bowel syndrome (IBS), chronic diarrhea, chronic constipation, coeliac disease, bowel resection or bariatric surgery)
- No acute diarrhea/gastrointestinal symptoms within the 2 weeks prior to donating
- No family history of any significant gastrointestinal conditions (e.g., family history of inflammatory bowel disease (IBD) or colorectal cancer)
- No history of atopy (e.g., asthma, eosinophilic disorders)
- Does not suffer from any systemic autoimmune conditions
- Does not start any new treatment regimens within 2 weeks of fecal collection
- No neurological or psychiatric conditions or known risk for prion disease
- No history of chronic pain syndromes, including chronic fatigue syndrome and fibromyalgia
- No history of receiving growth hormone, insulin from cows or clotting factor concentrates
- Has not received an experimental drug or vaccine within the past 6 months
- No history of travel to tropical countries within the past 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: standard of care (SoC) (IO±CTX) + FMT
Subjects assigned to Arm 1 will be required to swallow FMT capsules in a regimen of ten capsules in the morning and ten capsules in the afternoon on day 1 of the first (chemo-)immunotherapy cycle, and then every three weeks. abbreviation: Immuno-Oncology (IO) Chemotherapy (CTX) |
Recipients will undergo bowel preconditioning with antibiotics (Rifaximin) following randomization.
Other Names:
FMT involves the transplantation of fecal bacteria from a screened donor to a recipient.
This will be achieved per os in the form of a capsule containing freeze-dried stool obtained from the donor.
|
No Intervention: standard-of-care treatment
Subjects will receive standard-of-care treatment only.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS)
Time Frame: up to 2 years
|
PFS is defined as the time passed from screening until the date of progressive disease (PD) or death from any cause.
Imaging will be performed using computed tomography (CT) and/or Positron emission tomography (PET).
|
up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: up to 4 years
|
OS is defined as the time passed from randomization until death from any cause.
|
up to 4 years
|
Objective response rate (ORR)
Time Frame: From randomization (Day 0) until end of study
|
ORR is defined as the percentage of subjects who had a complete response (CR) or partial response (PR), as defined by ir-RECIST v1.1, and is based on the best response obtained.
|
From randomization (Day 0) until end of study
|
Rate of Disease Control
Time Frame: up to 2 years
|
Rate of Disease Control is defined as the percentage of subjects who had a complete response (CR), partial response (PR), or stable disease (SD), as defined by ir-RECIST v1.1.
|
up to 2 years
|
Microbiome analysis
Time Frame: up to 2 years
|
Microbiome analysis of the stool of donors and recipients (before and after FMT) to reveal the optimum microbiome-based components to significantly increase cancer immunotherapy efficacy
|
up to 2 years
|
Serum antibody levels and lymphocyte subpopulation distribution
Time Frame: up to 2 years
|
Analysis of serum antibodies and blood lymphocyte repertoires to be correlated to gut microbes and yeasts via blood samples of donors and recipients at several timepoints prior and post FMT induction
|
up to 2 years
|
Safety and feasibility
Time Frame: up to 2 years
|
Number of adverse events and serious adverse events related definitely to fecal microbiota transplantation (FMT).
|
up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ismaell Massalha, MD, Soroka University Medical Center
Publications and helpful links
General Publications
- Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.
- Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020 Jul 30;11(1):3801. doi: 10.1038/s41467-020-17670-y.
- Chen D, Wu J, Jin D, Wang B, Cao H. Fecal microbiota transplantation in cancer management: Current status and perspectives. Int J Cancer. 2019 Oct 15;145(8):2021-2031. doi: 10.1002/ijc.32003. Epub 2018 Dec 30.
- Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, Zidi B, Zhang S, Badger JH, Vetizou M, Cole AM, Fernandes MR, Prescott S, Costa RGF, Balaji AK, Morgun A, Vujkovic-Cvijin I, Wang H, Borhani AA, Schwartz MB, Dubner HM, Ernst SJ, Rose A, Najjar YG, Belkaid Y, Kirkwood JM, Trinchieri G, Zarour HM. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 2021 Feb 5;371(6529):595-602. doi: 10.1126/science.abf3363.
- Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G, Boursi B. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021 Feb 5;371(6529):602-609. doi: 10.1126/science.abb5920. Epub 2020 Dec 10.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- sor 0173-21 ctil
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Lung Cancer
-
Advaxis, Inc.TerminatedMetastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer MetastaticUnited States
-
Gottfried MayaUnknownMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Gastric Cancer | Metastatic Bladder CancerIsrael
-
Cota Inc.Blue Cross Blue Shield; NantHealth Inc.TerminatedPancreatic Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Melanoma | Metastatic Prostate Cancer | Metastatic Colon CancerUnited States
-
OBI Pharma, IncCompletedMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Gastric CancerTaiwan
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Williams Cancer FoundationSyncromune, Inc.RecruitingCancer | Solid Tumor | Metastatic Cancer | Metastatic Lung Cancer | Metastatic Breast CancerMexico
-
Asana BioSciencesCompletedCancer | Neoplasm Metastasis | Pancreatic Cancer | Metastatic Cancer | Metastatic Lung Cancer | Pancreas Adenocarcinoma | Metastatic Melanoma | Colon Cancer | Colonic Neoplasms | Pancreas Cancer | Non Small Cell Lung Cancer Metastatic | Neoplasm | Pancreas Neoplasm | Metastatic Pancreatic Cancer | Metastatic Colon Cancer and other conditionsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliInstitut Català d'Oncologia; Hospital Universitario Ramon y Cajal; Hospital Arnau... and other collaboratorsRecruitingMetastatic Colorectal Cancer | Metastatic Lung Cancer | Metastatic Breast Cancer | Metastasis | Metastatic Prostate CancerSpain
-
Genentech, Inc.CompletedNon-Small Cell Lung Cancer, Metastatic Colorectal Cancer, Metastatic Non Small Cell Lung Cancer, Metastatic Cancers, MelanomaUnited States
-
Yale UniversityNational Cancer Institute (NCI)TerminatedCancer Head Neck | Metastatic Cancer | Metastatic Lung CancerUnited States
Clinical Trials on Antibiotics
-
Eastern Virginia Medical SchoolNot yet recruitingPreterm Premature Rupture of Membrane
-
Centre Hospitalier Universitaire, AmiensRecruiting
-
Rush University Medical CenterRothman Institute OrthopaedicsCompletedArthroplasty | InfectionUnited States
-
Atlantic Health SystemRecruitingStress Urinary Incontinence | Postoperative Urinary Tract Infection | Urethral BulkingUnited States
-
Southern Illinois UniversityWashington University School of MedicineCompleted
-
Prisma Health-UpstateTerminated
-
Brigham and Women's HospitalDana-Farber Cancer InstituteNot yet recruitingFebrile Neutropenia | Hematologic Malignancy | Antibiotic Stewardship
-
Washington University School of MedicineSt. Louis UniversityTerminatedThe Primary Outcome of This Study Will be the Rate of EndometritisUnited States
-
Mount Sinai Hospital, CanadaUnity Health Toronto; The Ottawa Hospital; Sault Area Hospital; Michael Garron...RecruitingInfectious DiseaseCanada
-
Children's Hospital of PhiladelphiaCompletedAcute Otitis Media | Acute Sinusitis | Group A Streptococcal PharyngitisUnited States